

Appendix 4C

Quarterly report for entities admitted on the basis of commitments

Introduced 31/3/2000. Amended 30/9/2001, 24/10/2005, 17/12/10

Name of entity

BIONOMICS LIMITED

ABN

53 075 582 740

Quarter ended ("current quarter")

31-Dec-14**Consolidated statement of cash flows**

		Current quarter \$A'000	Year to date (6 months) \$A'000
Cash flows related to operating activities			
1.1	Receipts from customers	1,707	23,035
1.2	Payments for		
	(a) staff costs	(377)	(674)
	(b) advertising & marketing	(80)	(165)
	(c) research & development (incl. R&D staff costs)	(6,161)	(10,815)
	(d) leased assets	(96)	(157)
	(e) other working capital	(711)	(1,583)
		0	0
1.3	Dividends received	0	0
1.4	Interest and other items of a similar nature received	113	162
1.5	Interest and other costs of finance paid	(55)	(62)
1.6	Income taxes paid	0	0
1.7	Other	0	7,503
	Net operating cash flows	(5,660)	17,244
1.8	Net operating cash flows (carried forward)	(5,660)	17,244
Cash flows related to investing activities			
1.9	Payment for acquisition of:		
	(a) businesses (item 5)	(391)	(391)
	(b) equity investments	0	0
	(c) intellectual property	0	0
	(d) physical non-current assets	0	0
	(e) other non-current assets	0	0
1.10	Proceeds from disposal of:	0	0
	(a) businesses (item 5)	0	0
	(b) equity investments	0	0
	(c) intellectual property	0	0
	(d) physical non-current assets	0	0
	(e) other non-current assets	0	0
1.11	Loans to other entities	0	0
1.12	Loans repaid by other entities	0	0
1.13	Other	0	0
	Net investing cash flows	(391)	(391)
1.14	Total operating and investing cash flows	(6,051)	16,853

	Current quarter \$A'000	Year to date (6 months) \$A'000
Cash flows related to financing activities		
1.15 Proceeds from issues of shares, options, etc.	33	33
1.16 Proceeds from sale of forfeited shares	0	0
1.17 Proceeds from borrowings	11,468	11,468
1.18 Repayment of borrowings	(516)	(516)
1.19 Dividends paid	0	0
1.20 Other	0	0
Net financing cash flows	10,985	10,985
Net increase (decrease) in cash held	4,934	27,838
1.21 Cash at beginning of quarter/year to date	33,411	10,503
1.22 Exchange rate adjustments to item 1.20	24	28
1.23 Cash at end of quarter:	38,369	38,369

Payments to directors of the entity and associates of the directors

Payments to related entities of the entity and associates of the related entities

	Current quarter \$A'000
1.24 Aggregate amount of payments to the parties included in item 1.2	(285)
1.25 Aggregate amount of loans to the parties included in item 1.11	0
1.26 Explanation necessary for an understanding of the transactions	
Consists of remuneration paid to directors including remuneration paid to the Chief Executive Officer and Managing Director.	

Non-cash financing and investing activities

- 2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

N/A

- 2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

N/A

Financing facilities available

Add notes as necessary for an understanding of the position. (See AASB 1026 paragraph 12.2).

	Amount available \$A'000	Amount used \$A'000
3.1 Loan facilities - Line of Credit	12,018	12,018
3.2 Credit standby arrangements	0	0

Explanation necessary for an understanding of financing facilities available

Silicon Valley Bank non-dilutive funding as announced on 11 November 2014, fully drawn

Reconciliation of cash

Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.

		Current quarter \$A'000	Previous quarter \$A'000
4.1	Cash on hand and at bank	15,718	11,095
4.2	Deposits at call	22,651	22,316
4.3	Bank overdraft		
4.4	Other (provide details)		
Total: cash at end of quarter (item 1.23)		38,369	33,411

Acquisitions and disposals of business entities

		Acquisitions \$A'000 (Item 1.9(a))	Disposals (Item 1.10(a))
5.1	Name of entity	Prestwick Chemical	
5.2	Place of incorporation or registration	France	
5.3	Consideration for acquisition or disposal	\$391k	
5.4	Total net assets		
5.5	Nature of business	Medicinal chemistry services and smart screening libraries.	

Compliance statement

1 This statement has been prepared under accounting policies, which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.

2 This statement does ~~/does not*~~ (delete one) give a true and fair view of the matters disclosed.

Sign here:
(CEO & Managing Director)

30/01/2015

Print name: DEBORAH RATHJEN

Notes

- 1 The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity wanting to disclose additional information is encouraged to do so, in a note or notes attached to this report.
- 2 The definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report except for any additional disclosure requirements requested by AASB 107 that are not already itemised in this report.
- 3 **Accounting Standards.** ASX will accept, for example, the use of International Financial Reporting Standards for foreign entities. If the standards used do not address a topic, the Australian standard on that topic (if any) must be complied with.